恶性肿瘤输血研究新进展  

Progress on research on blood transfusion in malignant tumor

作　　者：唐求[1] 尹建平[2] 

机构地区：[1]武汉市中心医院肿瘤科,湖北武汉430020 [2]武汉血液中心

出　　处：《中国输血杂志》2015年第7期850-855,共6页Chinese Journal of Blood Transfusion

基　　金：湖北省自然科学基金重点项目(2015CFA082);湖北省卫生计生委科研项目(WJ2015CA002);武汉市临床医学科研项目(WX15D65)

摘　　要：几十年来,输血对恶性肿瘤生存与复发负面影响的临床回顾性研究报道是有争论的。但最近输血与肿瘤复发的动物模型、导致肿瘤复发和转移的血液基因蛋白质分子提供了可信证据。本综述归纳最近几年的相关研究报道,总结某些血型抗原与某些恶性肿瘤易感性关系,分析输血对恶性肿瘤特异性影响和临床结局的相关性,讨论恶性肿瘤输血风险及并发症、输血适宜性及输血策略,提出恶性肿瘤输血应该从自由性输血转变为限制性输血的建议。For decades,the retrospective clinical study on the association of negative impact of blood transfusion and the recurrence of malignant tumor and survival has been controversial. In recent years,however,the convincing evidence was provided by an animal model study on the association of clinical use of blood transfusion and malignant tumor recurrence,blood proteins,gene causative tumor recurrence and metastasis. This review summarized the relationship of malignant tumors with transfusion and the susceptibility of blood group antigens to some malignant tumors. Also,it analyzed the abnormal impact of blood transfusion on malignant tumor and its correlation with clinical outcome,discussed the risks in blood transfusion and its possible complications in malignant tumors. In addition,suggestions and strategies were provided for appropriate usage of blood transfusion. The paper recommended to adopt restrictive blood transfusion to replace liberal blood transfusion.

关 键 词：恶性肿瘤 输血 输血风险 输血相关性并发症 肿瘤复发 

分 类 号：R730[医药卫生—肿瘤] R457.1[医药卫生—临床医学]